01:10 PM EDT, 05/31/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We keep our 12-month target price at $103, on a forward P/E of 26x our FY 2025 (Oct.) earnings estimate, a modest discount to the company's five-year historic average at 27.7x. We raise our FY 2024 EPS view by $0.02 to $3.56 and increase FY 2025's by $0.02 to $3.95. COO posted Q2 FY 2024 EPS of $0.85 vs. $0.77 a year ago, $0.02 above consensus. Total revenue of $943 million missed consensus by 0.7% but was up 7.5% Y/Y. COO noted that the contact lens market grew 5% in calendar Q1, but that COO grew 7%, indicative of some market share expansion that we think is tied to product innovation. On the other hand, the CooperSurgical business grew a lackluster 4% in FQ2, which management attributed to systems upgrade interruptions. COO has maintained its full-year guidance for organic revenue growth (7.5%-8.5% range), which implies some acceleration in the latter half of FY 2024, especially in CooperSurgical, which may be difficult given relatively stronger comps from 2H FY 2023.